Nicoya, a leading provider of advanced analytical instruments for the biotechnology and pharmaceutical industries, announced today that they will be offering Surface Plasmon Resonance (SPR) technical support to all researchers – at no cost – during COVID-19.

The global impact of COVID-19 has made SARS-CoV-2 vaccine development a priority for researchers around the world. Finding a solution involves understanding the molecular characteristics of the virus through structural data, binding affinity and kinetics. SPR technology allows researchers to obtain this data in real-time and without the use of labels.

To help accelerate COVID-19 research and support the scientific community, Nicoya is offering SPR support for data analysis or experimental design at no cost. With this initiative, Nicoya aims to help researchers obtain high-quality binding kinetics data faster so they can better understand disease pathways, lead generation, and candidate validation. Researchers interested in requesting SPR support can do so at nicoyalife.com/covid-19-spr-support.

“Nicoya has a long history of standing behind scientists,” said Ryan Denomme, co-founder and CEO of Nicoya. “Now that this epidemic has brought their work to the forefront, it’s even more important that we do what we can to empower scientific research.”

Nicoya’s mission is to improve human life by helping scientists succeed. With the launch of this new initiative, the company aims to support the scientific community and accelerate COVID-19 research. For a full list of ways Nicoya is supporting researchers in the fight against COVID-19, including their latest research on the binding of a SARS-CoV-2 antibody to the SARS-CoV-2 spike protein receptor binding domain, visit their website.

The post Nicoya provides complimentary Surface Plasmon Resonance support for researchers during COVID-19 appeared first on Communitech News.

Communitech is a partner of Startup HERE Toronto.  This article originally appeared on their site.